Email ID
Password
Scrip   
BioCryst prices offering at $49 million
23 November 2009
Christopher Spillane

BioCryst Pharmaceuticals, a developer of small molecules to treat cancer and inflammatory and infectious diseases, is planning to raise $48.7 million in a public offering.

The company will use the proceeds to fund the clinical development of its purine nucleoside phosphorylase (PNP) inhibitors...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36